John McDonough is the President and CEO of T2 Biosystems, which focuses on developing innovative diagnostic products to improve patient health.
John held various positions at Cytyc Corporation, a company engaged in the design, development, manufacturing and marketing of clinical products that focus on women’s health, and ultimately served as President at Cytyc Development Corporation.
John led the expansion of the company’s single product with revenue of approximately $300 million to a diverse women’s health company with revenue of approximately $750 million. He led the efforts that resulted in Cytyc’s acquisition by Hologic, Inc. in October, 2007, for over $6 billion. John has served in senior executive management and CEO roles in several private and public companies. He is currently a member of the Board of Directors at Solace Therapeutics and Cytrellis Biosystems. John earned his B.S.B.A. from Stonehill College.
